Navigation Links
Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results
Date:8/4/2011

NASHVILLE, Tenn., Aug. 4, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced second quarter 2011 financial results.

Net Revenue:  For the three months ended June 30, 2011, net revenue was $14.4 million, up 34% from $10.7 million in the prior year period. The growth in revenue was due to an increase in sales volume for Acetadote following the Company's introduction of the new formulation for that product.

For the six months ended June 30, 2011, net revenue was $25.1 million, up 20% compared with $20.9 million for the six months ended June 30, 2010. This increase was largely attributable to the growth in net revenue during the second quarter of 2011.

Operating Expenses:  Total operating expenses for the three months ended June 30, 2011, were $10.8 million compared with $9.7 million for the prior year period. The difference related primarily to increases in cost of products sold during the quarter as well as increases in general and administrative expenses.  For the six months ended June 30, 2011, total operating expenses were $20.0 million compared with $19.1 million for the six months ended June 30, 2010.

EBITDA:  Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) for the three months ended June 30, 2011, were $3.9 million, up from $1.2 million for the prior year period.  EBITDA for the six months ended June 30, 2011, grew to $5.6 million, up from $2.3 million for the prior year period. The increase was primarily due to net revenue growth in the second quarter of 2011.

Net Income:  Net income attributable to common shareholders for the three months ended June 30, 2011, was $2.2 million, or $0.11 per diluted share, up 658% from $0.
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
3. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
4. Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
5. Cumberland Pharmaceuticals Partners in Canada With Alveda Pharmaceuticals to Commercialize Caldolor(R)
6. Cumberland Pharmaceuticals To Announce First Quarter 2010 Financial Results on May 13, 2010
7. Cumberland Pharmaceuticals to Present at Jefferies Global Life Sciences Conference in New York on June 8, 2010
8. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
9. Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
10. Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application
11. Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... -- Hyland Software expands upon its extensive expertise ... Clinical Leadership Team. Led by nurses and comprised ... healthcare experience, the team will leverage its knowledge ... solutions that will enhance the clinical experience and ... Healthcare organizations use OnBase, Hyland Software,s ...
(Date:5/20/2013)... May 20, 2013  Rhythm announced today the presentation ... higher prevalence of gastroparesis symptoms among diabetic patients in ... is high among patients with both type 1 and ... among those with the more common type 2 disease. ... MD, PhD, Associate Professor of Medicine at Harvard Medical ...
(Date:5/20/2013)... , May 20, 2013 Decision Resources, ... firms for pharmaceutical and healthcare issues, finds that ... offering a greater effect on quality of life ... Given the high level of subjectivity and variability ... interviewed thought leaders state that it is difficult ...
Breaking Medicine Technology:Hyland Software Forms Multi-Disciplinary Clinical Leadership Team to Augment Healthcare Solutions 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs 2
... Jennerex,Inc. (San Francisco, CA and Ottawa, Ontario), and ... of the first five patients in a,Phase 2 primary ... JX-594. No significant toxicities were reported, and enrollment of,patients ... The Phase 2 trial involves treatment of patients ...
... Pulmo BioTech Inc. has completed a dual listing. The ... (symbol PBO) in addition to the OTC BB (OTC ... role in the future development and financing of the ... the United States and Canada" - Garry McCann, CEO ...
Cached Medicine Technology:Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 2Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 3Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 4Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse 2Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse 3
(Date:5/20/2013)... New York, NY (PRWEB) May 20, 2013 ... to protecting the rights of victims injured by defective ... South Dakota man who alleges that use of the ... The suit was filed on April 30, 2013, ... of Louisiana (Case No. 6:13-cv-0888), where it is one ...
(Date:5/20/2013)... 20, 2013 Mirena IUD lawsuit ... multidistrict litigation recently established in U.S. District Court, Southern ... According to court records, the litigation’s first Status Conference ... to Plaintiff’s leadership positions were discussed. So far, ... Southern District of New York, all of which allege ...
(Date:5/20/2013)... 2013 Salt Lake Community College’s Know Greater ... Select 25 winners for 2013. As part of the ... Greater Heroes is a leadership training program that involves SLCC ... how to eat right, be active, and avoid drugs and ... Greater Heroes program each year, and visit more than 30 ...
(Date:5/20/2013)... judge overseeing pretrial proceedings in the federal consolidation of ... to be included in a plaintiffs’ leadership committee, according ... judge’s request, noting that its lawyers can help ... side effects and how to file a lawsuit. , ... female lawyers to the committee. This followed requests from ...
(Date:5/20/2013)... Amsterdam, NL, 20 May 2013 While Huntington,s ... community anticipates that new disease-modifying therapies in development ... success of HD research depends upon the identification ... and evaluate therapies, and these biomarkers may eventually ... Biomarkers could be especially helpful to monitor changes ...
Breaking Medicine News(10 mins):Health News:Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 3Health News:SLCC Know Greater Heroes Program Named to Select 25 2Health News:SLCC Know Greater Heroes Program Named to Select 25 3Health News:Mirena IUD Lawsuit Update: Judge Calls for More Input from Female Lawyers, Notes Rottenstein Law Group LLP 2Health News:Leading researchers report on the elusive search for biomarkers in Huntington's disease 2Health News:Leading researchers report on the elusive search for biomarkers in Huntington's disease 3
... wellbeing and inclusion of former politically motivated prisoners in ... (Monday 14 March). Ageing and Social Exclusion ... the border region of Ireland investigated the well being ... former prisoners (aged 50 and over) as older people ...
... (March 14, 2011) Research has shown that playing a ... children, but playing a used instrument also can pose a ... instruments were found to be heavily contaminated with a variety ... minor to serious infectious and allergic diseases, according to a ...
... (HealthDay News) -- Watching this year,s NCAA March Madness basketball ... on the games, one expert suggests. Though the current ... boards seems to suggest that predicting the outcome of games ... Nowlis, a marketing professor at the Olin Business School at ...
... to resist the targeted drug Herceptin, but a single ... vulnerability to treatment, scientists at The University of Texas ... Nature Medicine . Adding the drug saracatinib to ... at least five different molecular pathways, each of which ...
... , FRIDAY, March 11 (HealthDay News) -- People would prefer ... especially if they know others are watching, says a new ... likely to think badly of them if they do something ... to the research in the journal Psychological Science . ...
... March 11 (HealthDay News) -- A doctor,s empathy can improve ... important part of being a good doctor, according to a ... between July 2006 and June 2009 by 29 doctors at ... doctors, level of empathy for patients, while the quality of ...
Cached Medicine News:Health News:Report into well-being and inclusion of former politically motivated prisoners 2Health News:Report into well-being and inclusion of former politically motivated prisoners 3Health News:Is your child's hobby making him sick? 2Health News:Combination overcomes breast cancer resistance to herceptin 2Health News:Combination overcomes breast cancer resistance to herceptin 3Health News:When Someone Is Watching, You're Less Inclined to Do Bad Things 2
XL STABI Hydrophilic Acrylic Lens....
XL OCTO Hydrophilic Acrylic Lens....
One piece multifocal acrylic intraocular lens....
MemoryLens Prefolded Acrylic Lens....
Medicine Products: